Caprion Pharmaceuticals will contribute protein targets to Centocor Research and Development for the development of Mabs and other therapeutic products for various cancer indications under a recent license agreement between the two companies.
Caprion will select promising cancer targets using its CellCarta® proteomics technology platform. Centocor will have exclusive, worldwide rights to develop and commercialize therapeutics against any target it selects.
The financial terms of the agreement include an upfront payment, license fees, milestone payments relating to the development of products by Centocor, and royalties on commercial sales of such products.